Ainars Rudzitis

Prof. Ainars Rudzitis

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 October 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
EPEmilija V. Plorina
Emilija V. Plorina
KSKristine Saulus
Kristine Saulus
ARAinars Rudzitis
Ainars Rudzitis
Norbert KissNorbert Kiss
Norbert Kiss
MMMárta Medvecz
Márta Medvecz
ILIlze Lihacova
Ilze Lihacova
Neurofibromatosis type 1 (NF1) is a rare disease, affecting around 1 in 3500 individuals in the general population. The rarity of the disease contributes to the scarcity of the available diagnostic and therapeutic approaches. Multispectral imaging is a non-invasive imaging method that shows promise in the diagnosis of various skin diseases. The device utilized for the present study consisted of four sets of narrow-band LEDs, including 526 nm, 663 nm, and 964 nm for diffuse reflectance imaging and 405 nm LEDs, filtered through a 515 nm long-pass filter, for autofluorescence imaging. RGB images were captured using a CMOS camera inside of the device. This paper presents the results of this multispectral skin imaging approach to distinguish the lesions in patients with NF1 from other more common benign skin lesions. The results show that the method provides a potential novel approach to distinguish NF1 lesions from other benign skin lesions.

1 December 2016 in European Journal of Internal Medicine
Verified
Journal Article
Closed access
ASAndris Skride
Andris Skride
KSKristaps Sablinskis
Kristaps Sablinskis
Aivars LejnieksAivars Lejnieks
Aivars Lejnieks
ARAinars Rudzitis
Ainars Rudzitis

30 March 2024 in Medicina
Verified
Journal Article
Open access
PDF file
AKAnna Krigere
Anna Krigere
VKVerners Roberts Kalējs
Verners Roberts Kalējs
RKRicards Kaulins
Ricards Kaulins
ARAinars Rudzitis
Ainars Rudzitis
LBLīga Bondare
Līga Bondare
ASAndris Skride
Andris Skride
Background: Treatment options for inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or persistent pulmonary hypertension after pulmonary endarterectomy (PEA) include targeted medical therapy and balloon pulmonary angioplasty (BPA). BPA is an emerging treatment modality that has been reported to improve functional capacity, pulmonary hemodynamics, and right ventricular function. Reports from expert centers are promising, but more data are needed to make the results more generalizable. Materials and Methods: We conducted a prospective analysis of nine consecutive CTEPH patients who underwent balloon pulmonary angioplasty (BPA) sessions at Pauls Stradins Clinical University Hospital in Riga, Latvia between 1 April 2022 and 1 July 2023. We assessed World Health Organization (WHO) functional class, 6 min walk distance (6MWD), blood oxygen saturation (SpO2), brain natriuretic peptide (BNP) level at baseline and 3 months after the first BPA session. For two patients on whom repeated BPA sessions were performed, we additionally assessed cardiac output (CO), pulmonary vascular resistance (PVR), and mean pulmonary artery pressure (mPAP). Results: A total of 12 BPA procedures for nine patients were performed; repeated BPA sessions were performed for two patients. Our results show a reduction in BNP levels and improvement in WHO functional class, 6MWD, and SpO2 after the first BPA session. Improvement in 6MWD was statistically significant. Additionally, an improvement in pulmonary hemodynamic parameters was observed. Conclusions: Our data show that BPA is an effective interventional treatment modality, improving both the pulmonary hemodynamics and functional status. Moreover, BPA is safe and excellently tolerated.

21 June 2021 in Medical Sciences Forum
Verified
Conference Paper
Open access
PDF file
ATAgnete Teivāne
Agnete Teivāne
KJKristaps Jurjāns
Kristaps Jurjāns
ARAinars Rudzitis
Ainars Rudzitis
KLKrista Lazdovska
Krista Lazdovska
ABArturs Balodis
Arturs Balodis
EMEvija Miglane
Evija Miglane
Background and Objectives: According to guidelines, patent foramen ovale (PFO) closure is recommended for secondary stroke prevention in patients with cryptogenic stroke. Paradoxial embolism from PFO-mediated right to left shunt has been described as the mechanism of stroke in these cases. The aim of the study was to determine whether PFO closure can be associated with improvement of complaints (headaches, fatigue, heart palpitations, dizziness, and visual impairment) and determine its long-term effectiveness on recurrent stroke risk reduction. Materials and Methods: A total of 103 patients were enrolled in a retrospective study and followed-up by phone up to five years after PFO closure. Standardized survey was conducted about their well-being, recurrent cerebrovascular events, and the use of prescribed medication. Patients were also followed up for residual shunts 24 h, 30 days, 1 year, and 2 years after PFO. The pathogenic ischemic stroke subtypes are determined using CCS (Causative Classification System for Ischemic Stroke). Results: Male patients accounted for 43.7% (n = 45). The mean age was—44.4 ± 13 (18–75). The most probable cause for cryptogenic stroke for 53.4% (n = 55) of patients with possible cardio-aortic embolism was PFO. Residual shunts were mostly observed in patients with Amplatzer occluder—87.5% (n = 14). There was correlation between residual shunt and increased risk of transient ischemic attack recurrence (p = 0.067). Five-years after PFO closure recurrent cerebrovascular events were reported in only 5.1% (n = 5) of patients, this difference is statistically relevant (p < 0.001). Out of 51 patients presented with complaints before PFO closure, 25.5% (n = 13) did not present with any complaints after PFO closure. Conclusions: PFO can be considered a possible risk factor for cryptogenic stroke. PFO closure is effective in reducing recurrent cerebrovascular events. Residual shunt after PFO closure increases the risk of transient ischemic attack recurrence. Amplatzer occluder device is associated with a higher risk for residual shunts after PFO closure. PFO closure can be associated with improvement of complaints.

1 February 2018 in Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences.
Verified
Journal Article
Open access
PDF file
ARAinars Rudzitis
Ainars Rudzitis
KŠKristaps Šablinskis
Kristaps Šablinskis
BLBaiba Luriņa
Baiba Luriņa
ICIrina Cgojeva-Sproģe
Irina Cgojeva-Sproģe
AGAļona Grāve
Aļona Grāve
AĒAndrejs Ērglis
Andrejs Ērglis
Percutaneous transcatheter device closure of secundum atrial septal defects (ASD) has now largely replaced surgical closure in most centres. The aim of this study was to compare results of transcatheter and surgical ASD closure in adults in Latvia during the years 2002–2014 and to analyse long-term outcomes of transcatheter closure. We analysed data from 334 patients with secundum ASD who underwent ASD closure in Pauls Stradiņš Clinical University Hospital. Patients were included into device or surgical closure groups. In the device group, three follow-ups were made 1, 6, and 12 months after the procedure. No follow-up data were available for surgical arm patients beyond their hospitalisation period. The mean age of patients was 45.3 ± 19.9 years for the device group and 40.0 ± 16.9 years for the surgical group (p = 0.023). The mean secundum ASD size in the device and surgical groups was 14.2 ± 5.6 mm and 28.7 ± 10.0 mm, respectively (p < 0.001). No differences were observed regarding procedure success rates: 99.2% in the device group and 100% in the surgical group (p = 0.451). Periprocedural complications generally were more common in the surgical closure group. The study results show a successful introduction of the percutaneous ASD closure method in Latvia with good early and late outcomes and without significant differences in procedure success rate compared to surgical closure.

1 April 2021 in JACC
Verified
Journal Article
Closed access
ALArnis Laduss
Arnis Laduss
ECEvija Camane
Evija Camane
IPIlya Podolsky
Ilya Podolsky
AEAndrejs Erglis
Andrejs Erglis
KTKārlis Trušinskis
Kārlis Trušinskis
IKIndulis Kumsars
Indulis Kumsars